Psychedelic News and Analysis Made Simple for Investors

Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.

Track the entire psychedelic market

Track the entire psychedelic market

We’ve developed the first all encompassing index to track the public psychedelic marketplace.

Explore the Index

Just Some of the Data we Cover

Latest News

Health & Science

Psychedelic Retreats Market Set to Cross $1 Trillion By 2027

The market for psychedelic retreats is on a remarkable trajectory, with projections indicating it will surpass the $1 trillion mark by 2027. This anticipated milestone reflects the rapid expansion and increasing acceptance of psychedelic therapy as an effective treatment for various mental health conditions. The combination of scientific research, regulatory advancements, and shifting societal attitudes…

Health & Science

UC Berkeley’s Groundbreaking Study Exploring Psilocybin’s Effects on Perception

The UC Berkeley Center for the Science of Psychedelics has embarked on an unprecedented study to explore why psilocybin, a psychoactive compound found in certain mushrooms, alters visual perception in humans. This investigation represents the university’s first human trials involving a Schedule I substance, classified by the federal government as having no accepted medical use….

Health & Science

Lykos Therapeutics Addresses Concerns Over MDMA Treatment for PTSD

A week after an FDA committee voted against recommending midomafetamine (MDMA) treatment for post-traumatic stress disorder (PTSD), Lykos Therapeutics is working to clarify the situation and address concerns that have emerged in the broader conversation. This effort comes in the wake of significant public discourse surrounding the potential benefits and risks associated with the psychoactive…

Mindbloom Press

Largest Study of Psychedelic Medicine, with 11,441 Mindbloom Clients, Demonstrates Effectiveness and Safety of Guided At-Home Ketamine Therapy

AUSTIN, Texas, June 14, 2024 /PRNewswire/ — Mindbloom, the leading provider of psychedelic therapy, announced today the findings of the largest peer-reviewed study in the history of ketamine therapy and psychedelic medicine. The study was published in the Journal of Affective Disorders, and was authored by psychiatrists and researchers from Johns Hopkins University School of Medicine, NYU School of Medicine, the Institute for…

Filament Health Press

Filament Health Announces Closing of Warrant Exercise, Note Conversion and Concurrent Private Placement of Common Shares

VANCOUVER, BC, June 12, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today announces that, further to its press release dated June 3, 2024, it has completed its previously announced C$1.0 million bridge financing (the “Financing“). Pursuant to the Financing, Negev Capital Fund One, LP (“Negev“),…

Psyched Wellness Press

Psyched Wellness Developing Amanita Muscaria Gummies for Sale in the USA

Toronto, Ontario–(Newsfile Corp. – June 13, 2024) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is pleased to announce it will be releasing a new product this summer…

Press Release Press

Mindbio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial

MindBio Therapeutics Corp. reported positive secondary data from its world-first take-home microdosing depression trial using MB22001 completed earlier this year. Data from MindBio’s Phase 2A Depression trial indicates improvements in a range of secondary outcome measures following an 8-week treatment course with MB22001. This includes a 52% reduction in anxiety (HAM-A), and self-reported reductions in…

Explore the Psychedelic Landscape

Learn more about the psychedelic companies changing the industry.